ADI-001 — Interim data
H2 2026
The next clinical update on this trial is expected in the second half of 2026.Source filing
ACET biotech catalysts & pipeline
ADICET BIO INC · Data as of 2026-10-25
Upcoming catalysts
ADI-001 — Interim data
Q4 2026
Clinical update in patients with systemic sclerosis expected in the fourth quarter of 2026.Source filing
ADI-001 — FDA meeting
Q4 2026
The company plans to discuss with the FDA such potential expansion of the pivotal study to include lupus without nephritis in the fourth quarter of 2026.Source filing
ADI-001 — Clinical data readout
H1 2027
• First Half 2027: Anticipated clinical data update in systemic sclerosis (SSc)Source filing
ADI-212 — Initial data
1H27
First-Patient Dosing Anticipated in 4Q26 with Clinical Data Expected 1H27 & 2H27Source filing
ADI-001 — Clinical data readout
Mid 2027
• Mid 2027: Anticipated clinical data update in LN/SLESource filing
ADI-212 — Full data
2H27
First-Patient Dosing Anticipated in 4Q26 with Clinical Data Expected 1H27 & 2H27Source filing